Evidence mapPaperPMID 38978604Full record

ArticleResearch square2024

Diet induced insulin resistance is due to induction of PTEN expression.

Neal Rosen, Radha Mukherjee, Priya Pancholi, Malvika Sharma, Hilla Solomon, Merna Timaul, Claire Thant, Rory McGriskin, Omar Hayatt, Vladimir Markov and 6 more

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Neal RosenMemorial Sloan Kettering Cancer Center.ORCID 0000-0002-8307-654X
Radha MukherjeeMemorial Sloan Kettering Cancer Center.
Priya PancholiMemorial Sloan Kettering Cancer Center.
Malvika SharmaMemorial Sloan Kettering Cancer Center.
Hilla SolomonMemorial Sloan Kettering Cancer Center.
Merna TimaulMemorial Sloan Kettering Cancer Center.
Claire ThantMemorial Sloan Kettering Cancer Center.
Rory McGriskinMemorial Sloan Kettering Cancer Center.
Omar HayattMemorial Sloan Kettering Cancer Center.
Vladimir MarkovMemorial Sloan Kettering Cancer Center.ORCID 0000-0002-8190-3177
John D'AllaraMemorial Sloan Kettering Cancer Center.
Simona BekkerWeill Cornell Medicine.
Jacqueline CandelierMemorial Sloan Kettering Cancer Center.
Sebastian CarrascoMSKCC.
Elisa de StanchinaMemorial Sloan Kettering Cancer Center.
Kiran VanajaNortheastern University.

Funding

The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Type 2 Diabetes (T2D) is a condition that is often associated with obesity and defined by reduced sensitivity of PI3K signaling to insulin (insulin resistance), hyperinsulinemia and hyperglycemia. Molecular causes and early signaling events underlying insulin resistance are not well understood. Insulin activation of PI3K signaling causes mTOR dependent induction of PTEN translation, a negative regulator of PI3K signaling. We speculated that insulin resistance is due to insulin dependent induction of PTEN protein that prevent further increases in PI3K signaling. Here we show that in a diet induced model of obesity and insulin resistance, PTEN levels are increased in fat, muscle and liver tissues. Onset of hyperinsulinemia and PTEN induction in tissue is followed by hyperglycemia, hepatic steatosis and severe glucose intolerance. Treatment with a PTEN phosphatase inhibitor prevents and reverses these phenotypes, whereas an mTORC1 kinase inhibitor reverses all but the hepatic steatosis. These data suggest that induction of PTEN by increasing levels of insulin elevates feedback inhibition of the pathway to a point where downstream PI3K signaling is reduced and hyperglycemia ensues. PTEN induction is thus necessary for insulin resistance and the type 2 diabetes phenotype and a potential therapeutic target.

Identifiers

PMID38978604
PMCPMC11230483

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.